Evaluating Montreal's harm reduction interventions for people who inject drugs: protocol for observational study and cost-effectiveness analysis

被引:1
|
作者
Panagiotoglou, Dimitra [1 ]
Abrahamowicz, Michal [1 ,2 ]
Buckeridge, David L. [1 ,3 ]
Caro, J. Jaime [1 ,4 ,5 ]
Latimer, Eric [6 ,7 ]
Maheu-Giroux, Mathieu [1 ]
Strumpf, Erin C. [1 ,8 ]
机构
[1] McGill Univ, Sch Populat & Global Hlth, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada
[2] McGill Univ, Res Inst, Hlth Ctr, Montreal, PQ, Canada
[3] McGill Univ, Dept Med, Clin & Hlth Informat Res Grp, Montreal, PQ, Canada
[4] Evidera, Boston, MA USA
[5] London Sch Econ & Polit Sci, London, England
[6] Douglas Res Inst, Montreal, PQ, Canada
[7] McGill Univ, Dept Psychiat, Montreal, PQ, Canada
[8] McGill Univ, Dept Econ, Montreal, PQ, Canada
来源
BMJ OPEN | 2021年 / 11卷 / 10期
基金
加拿大健康研究院;
关键词
protocols & guidelines; public health; health policy; epidemiology; health economics; C VIRUS-INFECTION; TREATMENT STRATEGIES; HIV PREVENTION; CARE SERVICES; POPULATION; MODEL; IMPACT; USERS; TRANSMISSION; VALIDATION;
D O I
10.1136/bmjopen-2021-053191
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The main harm reduction interventions for people who inject drugs (PWID) are supervised injection facilities, needle and syringe programmes and opioid agonist treatment. Current evidence supporting their implementation and operation underestimates their usefulness by excluding skin, soft tissue and vascular infections (SSTVIs) and anoxic/toxicity-related brain injury from cost-effectiveness analyses (CEA). Our goal is to conduct a comprehensive CEA of harm reduction interventions in a setting with a large, dispersed, heterogeneous population of PWID, and include prevention of SSTVIs and anoxic/toxicity-related brain injury as measures of benefit in addition to HIV, hepatitis C and overdose morbidity and mortalities averted. Methods and analysis This protocol describes how we will develop an open, retrospective cohort of adult PWID living in Quebec between 1 January 2009 and 31 December 2020 using administrative health record data. By complementing this data with non-linkable paramedic dispatch records, regional monthly needle and syringe dispensation counts and repeated cross-sectional biobehavioural surveys, we will estimate the hazards of occurrence and the impact of Montreal's harm reduction interventions on the incidence of drug-use-related injuries, infections and deaths. We will synthesise results from our empirical analyses with published evidence to simulate infections and injuries in a hypothetical population of PWID in Montreal under different intervention scenarios including current levels of use and scale-up, and assess the cost-effectiveness of each intervention from the public healthcare payer's perspective. Ethics and dissemination This study was approved by McGill University's Institutional Review Board (Study Number: A08-E53-19B). We will work with community partners to disseminate results to the public and scientific community via scientific conferences, a publicly accessible report, op-ed articles and open access peer-reviewed journals.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Harm reduction interventions for people who inject drugs
    Nelson, Ediomo-Ubong
    [J]. LANCET GLOBAL HEALTH, 2023, 11 (05): : E632 - E633
  • [2] Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France
    Cousien, A.
    Tran, V. C.
    Deuffic-Burban, S.
    Jauffret-Roustide, M.
    Mabileau, G.
    Dhersin, J. -S.
    Yazdanpanah, Y.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2018, 25 (10) : 1197 - 1207
  • [3] Effectiveness and cost-effectiveness of improvements in harm reduction interventions, a better cascade of care, and Treat as Prevention of chronic hepatitis C in people who inject drugs (PWID) in France (ANRS 95146)
    Cousien, Anthony
    Tran, Viet Chi
    Deuffic-Burban, Sylvie
    Jauffret-Roustide, Marie
    Mabileau, Guillaume
    Dhersin, Jean-Stephane
    Yazdanpanah, Yazdan
    [J]. HEPATOLOGY, 2015, 62 : 1109A - 1109A
  • [4] Harm reduction among people who inject drugs in Mexico
    Magis-Rodriguez, Carlos
    Garcia-Sanchez, Jose Alfredo
    Marin-Navarrete, Rodrigo
    [J]. SALUD MENTAL, 2018, 41 (04) : 153 - 156
  • [5] Cost-Effectiveness Analysis of Brief and Expanded Evidence-Based Risk Reduction Interventions for HIV-Infected People Who Inject Drugs in the United States
    Song, Dahye L.
    Altice, Frederick L.
    Copenhaver, Michael M.
    Long, Elisa F.
    [J]. PLOS ONE, 2015, 10 (02):
  • [6] EFFECT OF COMBINED HARM REDUCTION STRATEGIES ON HCV INCIDENCE AMONG PEOPLE WHO INJECT DRUGS IN MONTREAL, CANADA
    Bruneau, J.
    Aswad, D. J.
    Zang, G.
    Roy, E.
    [J]. JOURNAL OF HEPATOLOGY, 2016, 64 : S462 - S462
  • [7] Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States
    Bernard, Cora L.
    Brandeau, Margaret L.
    Humphreys, Keith
    Bendavid, Eran
    Holodniy, Mark
    Weyant, Christopher
    Owens, Douglas K.
    Goldhaber-Fiebert, Jeremy D.
    [J]. ANNALS OF INTERNAL MEDICINE, 2016, 165 (01) : 10 - +
  • [8] Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs
    Sweeney, Sedona
    Ward, Zoe
    Platt, Lucy
    Guinness, Lorna
    Hickman, Matthew
    Hope, Vivian
    Maher, Lisa
    Iversen, Jenny
    Hutchinson, Sharon J.
    Smith, Josie
    Ayres, Rachel
    Hainey, Ingrid
    Vickerman, Peter
    [J]. ADDICTION, 2019, 114 (03) : 560 - 570
  • [9] Measures of harm reduction service provision for people who inject drugs
    O'Keefe, Daniel
    Bluthenthal, Ricky N.
    Kral, Alex H.
    Aitken, Campbell K.
    McCormack, Angus
    Dietze, Paul M.
    [J]. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2019, 97 (09) : 605 - 611
  • [10] HARM REDUCTION IN FIGHT AGAINST HIV Harm reduction interventions should encompass people who inject image and performance enhancing drugs
    McVeigh, Jim
    Kimergard, Andreas
    Bates, Geoff
    Hope, Vivian D.
    Ncube, Fortune
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2016, 353